Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced the initiation of a Phase 2 ...
Autobahn Therapeutics is a biopharmaceutical company that discovers and develops small molecule therapies to treat central nervous system disorders. The company’s pipeline products include ABX-002, a ...
Multiple Sclerosis companies are Immune Response BioPharma, Clene Nanomedicine, Genzyme, ImStem Biotechnology, Rho, Inc., ...
Zacks.com on MSN7d
Should You Retain Charles River Stock in Your Portfolio Now?Charles River Laboratories International, Inc.’s CRL RMS (Research Models and Services) segment is witnessing broad-based growth in all geographic regions for small research models. The company’s ...
The leading site for news and procurement in the pharmaceutical industry ...
Fifty years ago this month, an album was released in the U.S. that proved to be akin to a quake under a placid sea, one that created a ripple that grew into a tidal wave. That album was "Autobahn ...
In effect, this makes the Level 3 system functional on all 8,196 miles of the country's autobahn network, Mercedes-Benz notes, allowing the driver to text or even watch videos on their phone or ...
it arrives as the group celebrates the 50th anniversary of Autobahn, its breakthrough fourth album which helped electronic music gain a foothold in the US. Kraftwerk will boot up its Multimedia ...
Maxim Group analyst Jason McCarthy maintained a Buy rating on Capricor Therapeutics (CAPR – Research Report) yesterday and set a price target of $25.00. Discover the latest stocks recommended by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback